ATE383853T1 - Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit - Google Patents

Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit

Info

Publication number
ATE383853T1
ATE383853T1 AT05758960T AT05758960T ATE383853T1 AT E383853 T1 ATE383853 T1 AT E383853T1 AT 05758960 T AT05758960 T AT 05758960T AT 05758960 T AT05758960 T AT 05758960T AT E383853 T1 ATE383853 T1 AT E383853T1
Authority
AT
Austria
Prior art keywords
treatment
arylestic
alzheimer
disease
acids
Prior art date
Application number
AT05758960T
Other languages
English (en)
Inventor
Peter Blurton
Frank Burkamp
Ian Churcher
Timothy Harrison
Joseph Neduvelil
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE383853T1 publication Critical patent/ATE383853T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT05758960T 2004-07-23 2005-07-19 Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit ATE383853T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0416508.0A GB0416508D0 (en) 2004-07-23 2004-07-23 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE383853T1 true ATE383853T1 (de) 2008-02-15

Family

ID=32922716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05758960T ATE383853T1 (de) 2004-07-23 2005-07-19 Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit

Country Status (10)

Country Link
US (1) US20080300261A1 (de)
EP (1) EP1773315B1 (de)
JP (1) JP2008507498A (de)
CN (1) CN1993120B (de)
AT (1) ATE383853T1 (de)
AU (1) AU2005264004A1 (de)
CA (1) CA2574359A1 (de)
DE (1) DE602005004416T2 (de)
GB (1) GB0416508D0 (de)
WO (1) WO2006008558A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1650183A1 (de) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl)essigsäuren, ihre Derivate und Verwendung in der Therapie
SI1849762T1 (sl) * 2006-04-21 2009-12-31 Cellzome Ltd Substituirane bifenil karboksilne kisline in derivati le-teh
ES2333539T3 (es) 2006-04-21 2010-02-23 Cellzome Limited Derivados de terfenilo para el tratamiento de la enfermedad de alzheimer.
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2009036428A2 (en) * 2007-09-14 2009-03-19 Envivo Pharmaceuticals, Inc. 1,3,4-trisubstituted benzenes
WO2009052126A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE
CN101903335A (zh) 2007-10-19 2010-12-01 詹森药业有限公司 连接有胺的γ-分泌酶调节剂
KR101618068B1 (ko) * 2007-10-19 2016-05-04 얀센 파마슈티카 엔.브이. γ-세크레타아제의 탄소 결합된 조절제
KR20100090265A (ko) * 2007-10-19 2010-08-13 얀센 파마슈티카 엔.브이. γ-세크레타아제의 아미드 결합된 조절제
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US7968725B2 (en) * 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase
WO2010071741A1 (en) 2008-12-16 2010-06-24 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
MX2012005281A (es) * 2009-11-05 2012-06-19 Fibrostatin S L Inhibicion de gpbp utilizando peptidomimeticos q2.
JPWO2011062194A1 (ja) 2009-11-18 2013-04-04 武田薬品工業株式会社 アミノピリジン誘導体
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
WO2017139414A1 (en) 2016-02-09 2017-08-17 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (ido)
WO2023146513A1 (en) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Compounds and methods of use thereof
DE102024115190A1 (de) * 2024-05-31 2025-12-04 Technische Universität Bergakademie Freiberg, Körperschaft des öffentlichen Rechts 2-[(3,4,5-Triphenyl)phenyl]essigsäure und Derivate sowie deren Herstellung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325182A (ja) * 1995-05-31 1996-12-10 Fuji Yakuhin Kogyo Kk 置換テルフェニル誘導体とそれらを含有する抗血栓剤
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DE602005004416D1 (de) 2008-03-06
WO2006008558A1 (en) 2006-01-26
CN1993120B (zh) 2010-05-05
US20080300261A1 (en) 2008-12-04
DE602005004416T2 (de) 2009-01-08
GB0416508D0 (en) 2004-08-25
JP2008507498A (ja) 2008-03-13
EP1773315A1 (de) 2007-04-18
EP1773315B1 (de) 2008-01-16
CN1993120A (zh) 2007-07-04
AU2005264004A1 (en) 2006-01-26
CA2574359A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE455763T1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE529427T1 (de) Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE496534T1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
ATE549923T1 (de) Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties